A Very Difficult Launch

Quote
Think about this very closely. People who are hitting goal with Vesicare are surpassing goal by a few scripts weekly. Very rare to blow the numbers out at this point in the products life cycle. So having the first place product in the market and coming out with another will only affect the first place products share. Its common sense. We have no way around this. Even if you are really good and get some competition scripts to come over to the new product, Vesicare will still go down in numbers. Whatever marketing strategy they are coming up with, will not change the fact that Vesicare will be affected.

Plus, with quotas going up, and counting over 30 pills for a full script will hurt us even more. The good news is we will dominate this disease state, but we won't make much doing it.
 












I have never seen such a divide between managers and reps. It is like two different teams.

What the OP is saying is we use to get credit for 1 script of vesicare when dispensing 1 months worth of product. Now it takes 2 scripts, but less than the full 2 dispensed to get credit for 1 full script. We are now doing things on a fractional basis. Add about another 10 scripts to your weekly number. Thats what the real number should look like. All of this number manipulation is hurting us. Now more than ever because of the launch strategy.
 












Anonymous said:
I have never seen such a divide between managers and reps. It is like two different teams.

What the OP is saying is we use to get credit for 1 script of vesicare when dispensing 1 months worth of product. Now it takes 2 scripts, but less than the full 2 dispensed to get credit for 1 full script. We are now doing things on a fractional basis. Add about another 10 scripts to your weekly number. Thats what the real number should look like. All of this number manipulation is hurting us. Now more than ever because of the launch strategy.
Click to expand...

This is happening throughout the industry. I am with another company, and it now takes us 2 Rx's to get credit for 1 Rx towards our goals. Crazy formulas by a few creepy MBA graduates who never spent a day in the field. Top down management never worked for any entity, but it is the law of the land lately in business as well as government. Need to start rereading some of those old George Orwell books.
 






Anonymous said:
Well clearly we aren't as smart as you are. How about you get specific for us. When did I say I suck at selling? There a many more things that go into a launch than just sales skills. Just ask the APUS marketing team...wait, that won't work
Click to expand...

You seem to know a ton about what's going on and what's needed for launching a drug. Go on
Yoda and enlighten us. You apparently don't sell. You're just another can't do it by myself whiner. And the first to blame the marketing team when you can't sell your way out of a paper bag. All we really need is the PI, samples and some coupons
 






Anonymous said:
This is happening throughout the industry. I am with another company, and it now takes us 2 Rx's to get credit for 1 Rx towards our goals. Crazy formulas by a few creepy MBA graduates who never spent a day in the field. Top down management never worked for any entity, but it is the law of the land lately in business as well as government. Need to start rereading some of those old George Orwell books.
Click to expand...

How can this be
 






Hahhhaaaaaheeehee -- Did you say Vesicare's Product lifecycle.. HeeHee This is like a Bert & Ernie moment. You DO realize this drug is about 5 years past it's lifecycle. What a douche! You must be from the home office, where you just completed some bs program on studying rx product Lifecycles. Well - get a clue, Vesicare is now about to eclipse Bufferin's longevity on the Product Lifecycle you moron.
 












Anonymous said:
Hahhhaaaaaheeehee -- Did you say Vesicare's Product lifecycle.. HeeHee This is like a Bert & Ernie moment. You DO realize this drug is about 5 years past it's lifecycle. What a douche! You must be from the home office, where you just completed some bs program on studying rx product Lifecycles. Well - get a clue, Vesicare is now about to eclipse Bufferin's longevity on the Product Lifecycle you moron.
Click to expand...

Wrong. You could say that about the enitre anticholinergic class except Toviaz. Toviaz has had only about 2% to 4% share for the last three years. So I do not understand your comment. I am a rep not a manager or home office person. I do recognize we have a problem with launching with the specific strategy of not hurting Vesicare business.
 






"All we really need is the PI, samples and some coupons"

What year do you think it is? This is 2012. If you don't have MHC coverage, you don't launch. Not in this market. This is OAB. Cost rules. ...oh and having a new study in hand to launch a drug is hardly being demanding. Pretty standard stuff.
 






This is not meant to be a negative thread. We will have some MC coverage. I just do not see this happening without affecting Vesi scripts. Growing the market at this point is impossible if we have not done so already.
 






Anonymous said:
This is not meant to be a negative thread. We will have some MC coverage. I just do not see this happening without affecting Vesi scripts. Growing the market at this point is impossible if we have not done so already.
Click to expand...

You can't grow a market with a me-too drug you only steal share. Where you're an idiot and haven't been paying attention is this is a new MOA and new class of drug. And there is so much discontinuation on the current class that what you've lost sight of is the ability to either keep these patients in longer or get back those that may retry. If you've ever worked more than a year in this industry there are tons of examples of new classes of medications growing reenergizing or growing markets. So when you get your head out of wherever it is you'll see the opportunity. If not polish the CV up and apply at Warner Chilcott. They need more positive people like you
 






Leadership and reps need to be in synch during this critical launch phase. So what happened to Jay G? Another experienced manager given the axe? Launching a drug when morale is at an all time low requires real leadership at the top. Unfortunately we are in trouble.
 






Anonymous said:
You can't grow a market with a me-too drug you only steal share. Where you're an idiot and haven't been paying attention is this is a new MOA and new class of drug. And there is so much discontinuation on the current class that what you've lost sight of is the ability to either keep these patients in longer or get back those that may retry. If you've ever worked more than a year in this industry there are tons of examples of new classes of medications growing reenergizing or growing markets. So when you get your head out of wherever it is you'll see the opportunity. If not polish the CV up and apply at Warner Chilcott. They need more positive people like you
Click to expand...

Yes that is the answer to selling this drug the new MOA. Now we can launch. Thanks so much.
 






There are only so many OAB patients. Squeezing another product will only take away from every drug in that market. The only way around it is to keep the new product quiet. A last resort therapy before procedure. What management is not keeping in mind that M will be making money long after Vesicare is generic.
 


















Anonymous said:
Leadership and reps need to be in synch during this critical launch phase. So what happened to Jay G? Another experienced manager given the axe? Launching a drug when morale is at an all time low requires real leadership at the top. Unfortunately we are in trouble.
Click to expand...

Jay G from where? What territory/geography?
 






Anonymous said:
If you were asked by a customer, which one is the gold standard. What will you say
Click to expand...

Apply for a new job! This is a softball....Vesicare is the gold standard based on efficacy, tolerability and managed care coverage, the new product is a new class of drug and it will have its place in time. Wow we are in trouble with dumb asses like you!
 






Top Bottom
Back
Quote